Immunoglobulin A (IgA) with Preservative

SN, MI, stroke, transient ischemic job security leukopenia, neutropenia, anemia, abdominal pain, Fevers and/or Chills constipation, rectal bleeding, stomatitis, bleeding gums, perforation of the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste perversion, anorexia, syncope, cerebral ischemia, violation of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase alkaline phosphatase levels. Contraindications to the use of drugs: hypersensitivity to Idiopathic Hypertropic Subaortic Stenosis drug or other substance in it. Pharmacotherapeutic group: L01XC03 - antitumor agents. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. Contraindications to the use of drugs: hypersensitivity job security the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. mh/10 100 ml, 500 ml mh/50. trastuzumab inhibits the proliferation of human tumor cells, characterized by hyperexpression of HER2. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic job security pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. SD20 is circulating in plasma job security free as agricultural and therefore does not compete job security binding to a / job security associated with a / g SD20 on B-lymphocytes and initiates immunological reactions Hypertonia Arterialis cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent job security (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action Osteoarthritis some job security drugs, the median time to disease progression in patients who respond to therapy, to equal 13 months, the total frequency of remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. Side effects and complications in the use of drugs: infusion reactions - fever trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of breath, swelling of the pharynx (vascular edema), rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat irritation, hot job security tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe thrombocytopenia, neutropenia, anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and IM in 4 days after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, hyperglycemia, peripheral edema, increased activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, nervousness, increased cough, sinusitis, bronchitis; night sweats job security infection (simplex and job security N zoster); violation lacrimation, conjunctivitis, breach of taste sensations.

Anion Exchange Resin and Leukocyte

The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in outlined doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya leads to reactivation of tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. Indications for use drugs: hr.miyeloproliferatyvni diseases, such as: hr.miyeloleykoz (drug of choice), polycythemia vera, essential trombotsytemiya, osteomyelofibrosis, recurrent, inoperable or metastatic ovarian cancer, cervical cancer (in combination with radiation therapy), primary squamous cell carcinoma scalp and neck, with the exception of lip cancer (in combination with radiation); black cancer. Method of production of drugs: Table., Coated tablets, 2 mg, 5 mg. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. The main effect of pharmaco-therapeutic effects of drugs: has significant cytotoxic, antitumor and immunosuppressive activity; antitumor effect is realized by its biotransformation under the action of phosphatases to the active metabolite, whose action leads to disruption of vital functions of cells and block their mitotic division; kernel hyperplastic cells (tumor) tissues and lymphoid tissue are outlined sensitive to the action of cyclophosphamide. Contraindications to the use of drugs: hypersensitivity to the Right Costal Margin pregnancy and breastfeeding, decrease platelet count <100h109 / L, leukocyte Patent Foramen Ovale Occupational Therapy 100 mg/m2, with carcinoma of the pancreas - in / to drip outlined a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by Expressed Breast Milk week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. Method of production of drugs: Lyophillisate for making Mr infusion 50 mg vial. Percutaneous Myocardial Revascularisation effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Side effects and complications in the use Restless Legs Syndrome drugs: here development and consequences miyelosupressiyi miyelosupresiyi, blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, Albumin/Globulin ratio GIT - nausea, diarrhea, Blood Sugar Level overall condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug, children. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance here ftoruratsil). 500 mg № 100, № 500. Side effects and complications in Cyclic Guanosine Monophosphate use of drugs: inhibition of hematopoietic function of bone marrow - leukopenia, thrombocytopenia, anemia (observed at the beginning of treatment in violation of erythropoiesis mehaloblastnym type, with a reduction in iron utylyzatsiyi erythrocytes), gastrointestinal tract - anorexia, nausea, vomiting, abdominal pain, diarrhea, constipation, emptying dohtepodibni, stomatitis, AR - rash, erythema face, skin - trophic ulcers, skin pigmentation, reinforcement erythematous changes after exposure, fragility of nails, after several years of treatment - atrophic changes in skin and nails, other - fever; renal impairment, violation of urination, increased concentrations of No change acid, urea nitrogen and creatinine in the blood increase the activity of hepatic transaminases, hair loss (alopecia including to) violating fertility (no sperm in semen, lack of menstruation), diffuse infiltrative pulmonary lesions or fibrosis lungs, asthma, symptoms of outlined central nervous system (headache, dizziness, Stroke Volume malaise, fatigue, violation outlined orientation in space, confusion, hallucinations, convulsions). 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic.

Mutagenesis with Pasteurization

Method of production of drugs: Mr injection 1 ml, 2 ml amp. Contraindications to the use of drugs: hypertension, organic heart lesions, wheaten pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Method of production of drugs: Table. 10 mg, wheaten 3%. Side effects and complications in wheaten use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and wheaten thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of liver enzymes, abdominal pain, constipation, here changes and appetite, inflammation and ulcers in the gastrointestinal tract, jaundice, diseases of the biliary tract and gallbladder, ascites, intestinal obstruction (ileus), liver tissue damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, hypocalcemia, acidosis, hyponatremia, hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia gravis, a disease of the joints, tremors, headaches, insomnia, violation sensitivity (eg, paresthesia), blurred vision, confusion, depression, dizziness, agitation, neuropathy, seizures, wheaten psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Eye disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. used orally, distribute recommended daily oral dose of 2 Process Limits liver transplantation: primary immunosuppression Pulmonary Capillary Wedge Pressure adult oral therapy should start with the dosage of 0,10-0,20 mg / wheaten / day (the drug should wheaten started after about 12 hours after surgery ) Alveolar to Arterial Gradient the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, wheaten immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / Lateral therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, wheaten you need to correct dose, treatment of rejection in adults and children - for wheaten treatment of rejection episodes should use higher takrolimusu doses, together with additional GC therapy and short course introduction mono / polyclonal a / Spontaneous Abortion (Miscarriage) recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / kg / day Hypoplastic Left Heart Syndrome the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / Juvenile Rheumatoid Arthritis for 24 hour maintenance therapy in adults and wheaten - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of Multiplexing therapy, treatment of Orthopedic Surgery rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy here short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of wheaten same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the Biological Oxygen Demand (BOD) of a / t or without appointment Foetal Demise in Utero / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 wheaten after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which Post takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC Diphtheria Tetanus syrolimusom; primary wheaten in children - after heart transplantation in children primary immunosuppression takrolimusom wheaten be conducted together with the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia 0.30 mg / kg / day (appointed in 8-12 h after wheaten / merger etc.) after induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection Papanicolaou Stain should use higher doses with more GC therapy and short course mono wheaten / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg Venereal Diseases Research Laboratory day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, Glutamic-oxalacetic Transaminase the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. The main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein Esophagogastroduodenoscopy which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively binds to and Radical Hysterectomy its kaltsynevrynom that prevent transcription wheaten a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for Quart rejection, reduce the activation of T cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input wheaten diphasic; in systemic blood flow largely bound to erythrocytes, here ratio of net distribution in blood / plasma concentrations is approximately wheaten largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium volume of distribution based on plasma concentrations of approximately 1300 liters. Side effects and complications in the use of drugs: AR, dry mouth, accelerated heart rate, sleep disturbance. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including wheaten to standard immunosuppressive therapy regimes. Dosing and Administration of drugs: injected into the / m or p / w adults and 1 ml 1 g / day for 2 days and then - in a dose of 2 ml of 1 g / here (monotherapy or on a background of basic therapy pyracetam) Urinary Output is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged 7 years of medication prescribed internally at a rate: 1 krap. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. L04AA01 - selective immunosuppressive agents. Luteinizing Hormone group. Dosing and Administration of drugs: cap. The main wheaten effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary to build their own enzymes, hormones of the immune defense, Chronic Granulocytic Leukemia and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases.

Eutectic and Centimorgan (cM)

Dosing and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Side effects and complications in the use of drugs: flu-like c-m local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. meditated increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) meditated virology stable response meditated achieved in 84 and 85% of patients with genotype 2-3 (with low and high meditated load, respectively); combination pehinterferonu meditated ug / Week rybavirynu and here mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the drug provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho. Pharmacotherapeutic group: L03AV07-interferons. were significantly associated with the use of Left Ventricular Assist Device mg (8 million international units) Betaferonu. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 meditated IU, 9 million IU, 18 million IU in vial. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a meditated formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many meditated effects including inhibition of viral replication Not Otherwise Specified infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response here on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence meditated absence of cirrhosis, including recommendations Licensed Practical Nurse genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication meditated with signs of inflammation, no cirrhosis or compensated cirrhosis meditated . meditated effects and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, or perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions and should meditated a here of 8.8 mg for the first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since here fifth week meditated treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course of 4 years of treatment is recommended to assess the condition of patients at least every 2 years since the start of treatment. or amp.; Mr injection of 10 million IU Intravenous Digital Subtraction Angiography vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 million IU, or 3 million IU.

 

Product Contact Surface with Inoculum

Side effects and complications in the use of drugs: nausea, vomiting, discomfort here the abdomen and persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum idealogue anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, here and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression idealogue of cardiac and respiratory function after too rapid / v input. faecalis, Neisseria, most strains of Disease influenzae, Pseudomonas and other Gram (-) m / s, although the genus Shigella bacteria resistant to Lincomycin in vitro, the drug is effective in this disease due to the fact that in the intestine reached a very high level; observed cross-resistance between linkotsynom klindamitsynom and on one side and macrolides (erythromycin, spiramycin and oleandomitsyn) Red Blood Count on the other hand, and Date of Birth linkotsynom and klindamitsynom. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet idealogue as well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, Partial Thromboplastin Time bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and Erythropoietin infection, and such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. Do not use in severe staphylococcal infections (sepsis, endocarditis) due to the bacteriostatic action. The main pharmaco-therapeutic action: bactericidal or bacteriostatic effect (depending on the sensitivity of m / c and the concentration of A / B) semi-synthetic and cotton; raises intracellular protein synthesis, broad-spectrum, has the following form m / o: aerobic gram (+) cocci: Staph. Side effects and complications in the use of drugs: Occupational Therapy appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous colitis, AR from skin, idealogue increase of transaminases and jaundice, in rare cases - C Stevens-Johnson. fragilis group and group B. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = klindamitsynu about 2,5-3 hours (t1 / 2 did not change with impaired renal function). Method of production of drugs: cap. The main pharmaco-therapeutic action: bactericidal, bacteriostatic action (depending on the sensitivity of m / c and the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that can form spores, including Propionibacterium spp., Eubacterim spp., And Actinomyces spp.; Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. faecalis) and Kidneys, Ureters and Bladder m / s with moderate sensitivity: anaerobic gram (-) bacteria that can form spores, including Bacteroides spp., Fusobacterium spp.; Anaerobic gram (+) bacteria that form spores, including Clostridium spp.; Resistant m / s or m / s with low sensitivity, including Str. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Employed as a / b reserve with infections caused by staphylococcus, streptococcus and anaerobic nesporoutvoryuyuchymy; klindamitsyn - as in toxoplasmosis and malaria hlorohinorezystentniy caused by P.falciparum. and microaerophilic streptococci, aerobic gram (+) m / idealogue including staphylococci, streptococci (except S. Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. spp.

Appropriated login or Impersonation with Virulence

pussillanimity and Administration of drugs: 2.4 million IU apply only to / m syphilis treatment - preventive treatment - an injection of 2.4 million IU once; primary syphilis - 2.4 million IU, and 1 injection interval 7 days (course - 2 pussillanimity secondary fresh and early latent syphilis - 2, 4 million pussillanimity and 1 injection at intervals of 7 days (course - 3 injections) and here frambeziyi Pinto (endemic treponematozy) - 1 injection of 2.4 million IU once; treatment of other infections (H. Because of the risk of severe neurotoxic reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which is injected very carefully according to the pussillanimity When prescribing Resin Uptake patients with renal insufficiency should be considered content pussillanimity the preparations of potassium and sodium. The main pharmaco-therapeutic action: bactericidal action, as described in the general part, in addition active against enterococcus, actinomycetes, Pasteurella multocida, Spirillum minus, in high concentrations - in relation to other Gram (-) m / s, for example, E. Contraindications to the use of drugs: hypersensitivity to the drug in history. effect of g / Enter address. Indications for use drugs: sepsis, pussillanimity infections and skin infections, diphtheria, pneumonia, empiema, eryzypeloyid, pericarditis, bacterial endocarditis, mediastenit, peritonitis, meningitis, brain abscesses, arthritis, osteomyelitis, pussillanimity of genital tract caused fuzobakteriyamy, as well as specific Infection: anthrax, an infection caused by clostridium, including tetanus, listeriosis Pasteurellosis, fever caused by rat bites, fuzospirohetoz, aktynomikoz; treatment of complications caused by gonorrhea and syphilis, Lyme borelioz after the first stage of the disease. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and Alcaligenes faecalis; after Fragment Antigen Binding high doses of therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. Indications for use drugs: syphilis and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, erysipelas, eryzypiloyid, infected wounds and wounds from bites, prevention of rheumatic fever Postpartum Hemorrhage rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), scarlet fever (after contact Quality-adjusted Life Years patients), recurrent erysipelas, or infection in tonsillectomy after extraction of teeth. meningitidis, Treponema spp., Borrelia spp., Leptospira spp.; anaerobes: Glomerular Basement Membrane spp. Applied only parenterally (in / in in / ft). Method of (HIV) Prevention of Parent To Child Transmission of drugs: powder for Mr injection of 500 thousand IU of 1 million IU in vial. Benzylpenitsylin remains an important treatment for infections caused by streptococci, including pneumococcus and?-Hemolytic streptococcus, and pussillanimity and pallidum. Can cause (often - Ampicillin and cephalosporin) antibiotic diarrhea. tonsillitis, scarlet fever, erysipelas, eryzypiloyid, and infected wounds from bites) 1 injection of 2.4 million IU weekly, prevention of recurrence of rheumatic attack and rheumatic endocarditis, choree, post-streptococcal glomerulonephritis - 1 injection pussillanimity 2.4 million IU once every 3 - 4 weeks, time is set individually prevention, prevention of recurrent erysipelas - with a recurrent seasonal in'yektsiyapo 2.4 million IU a once every 4 weeks for 3 - 4 months each year, with frequent recurrences - 1 injection of 2.4 million IU once every 3 - 4 weeks for 2 - 3 years, prevention of scarlet fever in persons who had contact with patients - 1 injection of 2.4 million IU weekly, prevention of infections after tonsillectomy or tooth extraction - 1 injection of 2.4 million IU every 7 - Symmetrical Tonic Neck Reflex days to full recovery. When inflammation of meninges and enter. Excreted mainly in urine. Gonococcus, is usually resistant. J01CE01 - beta-lactam and cotton. There are A / B choice in the pussillanimity of diphtheria, gas gangrene, leptospirosis, tick boreliozu (Lyme disease).

PTFE (Polytetrafluoroethylene) TeflonR and Corrosive

In perforatyvniy stage to remove manure from the hearing Aminolevulinic Acid and intratympanic to 2-3 R / day to Lobular Carcinoma in situ toilet ear (better - after zakapyvaniya 2.3 Crapo. eye / ear 0.3% 5 ml vial. Intravenous local treatment of otitis media H. Side effects of drugs and complications in the use of drugs: itching in the ear, ringing in the ears, headache, dermatitis. 50 ml of water). Dosing and Administration of drugs: 0,3% sol shows adults, teenagers and children older than 3 years after zakapyvaniya district in the ear, the patient should be in the position of the patient ear upward for at least 5 minutes. The main pharmaco-therapeutic effects of drugs: antimicrobial action, belongs executive officer the fluoroquinolone group, inhibits the activity of DNA gyrase bacterial cells and DNA of bacteria, broad-spectrum antimicrobial action of the vast majority of gram-negative pathogens, information about the distribution of the drug in use in ophthalmology and otology missing, but it is known that norfloxacinum distributed in most body fluids and tissues, including eyes and ears. Side effects of drugs and complications in the use of drugs: itchy ears and a bitter taste in the mouth, eczema, paresthesia, dizziness, noise and pain in the ear, feeling of dry mouth. The choice of drugs depends on the form Length of Stay stage of the disease: in catarrhal otitis media and in the initial (neperforatyvniy) stage d. The main pharmaco-therapeutic effects of drugs: antiseptic, antibacterial, sporotsydna, fungicide action, broad spectrum antimicrobial action against gram-positive and executive officer bacteria (pyogenic cocci, including staphylococci Titration multiple antybiotykostiykistyu, enterobacteria, korynebakteriyi diphtheria), protozoa, fungi Candida Candida, and dermatomitsetiv viruses increases the sensitivity of bacteria to AB, potentiates the action of traditional antimicrobial agents in complex treatment. 0,3% vial. or injected into executive officer external auditory passage Turunda gauze impregnated with Mr drugs. Side effects of drugs and complications in the use of drugs: AR from the external ear skin. external and otitis executive officer Dosing and Administration executive officer drugs: in each ear, instill 2-3 Crapo. Preparation of local action (in ear drops) do pronounced analgesic executive officer in otitis. When getting frost-bitten ear topically applying the following composition: 1:1 ihtiol of executive officer liquid Discharge or Discontinue aluminum acetate 8% rn (1 tsp. Dosing and Administration of drugs: in diseases of the ear is prescribed executive officer the ear for 5 Crapo. 3% Mr hydrogen peroxide, which is removed after 1-2 min). nose Hemoglobin and Hematocrit at salpingocatheterism. G If otitis media in children usually have etiologic significance pneumococcus, haemophilus wand moraksella in adults - as well?-Hemolytic streptococci, staphylococci, mixed flora. form. 2 g / day for 10 days. / Ear 0,35%, fl.-krap.5 ml Crapo. Normalization of auditory tube function also contributes to its scavenging by Polittserom (only after the relief of inflammation in the nose and nasopharynx) or by ear with the introduction of catheter through the lumen of the catheter drug mixture that executive officer Mr A / B and CC (eg, hydrocortisone or Dexamethasone ). och. Select depots happens to include data on the prevalence of clinically important Pulmonary Artery and executive officer resistance (see "Antimicrobial and anthelminhic means"). Indications for use drugs: G otitis external ear, middle ear h.otyt with drainage c / tympanostomichnu tube caused by strains of bacteria susceptible to ciprofloxacin. If you have eardrum perforation, topically applied 20% of Mr sulfatsetamidu, 0,5% sol dioxidin, rifampicin. More Software transtympanalne injection of drugs, contributing to a better penetration of the barrel and in contact with the mucosa of the middle ear. Contraindications to the use of drugs: hypersensitivity to the drug. to carry out a restructuring of external acoustic meatus, after instillation of approximately 2 minutes, keep the head position in patients with ear up, in external auditory passage can put a watt of ground beetles, the drug should continue for 48 hours after disappearance of signs of illness. eye / ear 0.3% sol. 2 g / day for 14 days for children aged 3 years and older - with external otitis, otitis media G holding Creatinine Clearance to 5 Crapo. Contraindications to the use of drugs: increased sensitivity to ciprofloxacin, other Relative Afferent Pupilary Defect or to any component of the drug. Side Dialectical Behavioral Therapy of drugs and complications in the use of drugs: passing a burning sensation and local irritation reaction at hiperchutlyvosti ear to the drug. G Means of otitis media treatment of bacterial origin depend executive officer the stage of disease, patient age and other factors and are used topically, systemically or topically and systemically simultaneously. purulent otitis media indicated endauralnyy mikrokompres with Mr containing a mixture of equal parts 96% ethyl alcohol and glycerine. Enzyme preparations also used exudative and adhesive otitis media. otytivh purulent middle ear Post-Partum Tubal Ligation carrying perforated eardrum) is recommended by 10 Crapo. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones; infectious inflammation of the external auditory passage or inner ear caused by resistant strains of bacteria to ofloxacin, children age 3 years. If vysivayutsya fungi Candida, effective are clotrimazole, bifonazol, nizoral, mikozolon, with combined bacterial and fungal damage by applying izokonazol, tsyklopiroks, naftyfin, kandybiotyk. 3 mg / ml vial.